Literature DB >> 10737655

Protective immunity against Newcastle disease: the role of cell-mediated immunity.

D L Reynolds1, A D Maraqa.   

Abstract

The role of cell-mediated immunity (CMI) in protection of birds from Newcastle disease was investigated by two different strategies in which only Newcastle disease virus (NDV)-specific CMI was conveyed without neutralizing antibodies. In the first strategy, selected 3-wk-old specific-pathogen-free (SPF) birds were vaccinated with either live NDV (LNDV), ultraviolet-inactivated NDV (UVNDV), sodium dodecyl sulfate-treated NDV (SDSNDV), or phosphate-buffered saline (PBS) (negative control) by the subcutaneous route. Birds were booster vaccinated 2 wk later and challenged with the velogenic Texas GB strain of NDV 1 wk after booster. All vaccinated birds had specific CMI responses to NDV as measured by a blastogenesis microassay. NDV neutralizing (VN) and hemagglutination inhibition (HI) antibody responses were detected in birds vaccinated with LNDV and UVNDV. However, birds vaccinated with SDSNDV developed antibodies that were detected by western blot analysis but not by the VN or HI test. Protection from challenge was observed only in those birds that had VN or HI antibody response. That is, birds with demonstrable CMI and VN or HI antibody response were protected, whereas birds with demonstrable CMI but no VN or HI antibody response were not protected. In the second strategy, birds from SPF embryos were treated in ovo with cyclophosphamide (CY) to deplete immune cells. The birds were monitored and, at 2 wk of age, were selected for the presence of T-cell activity and the absence of B-cell activity. Birds that had a significant T-cell response, but not a B-cell response, were vaccinated with either LNDV, UVNDV, or PBS at 3 wk of age along with the corresponding CY-untreated control birds. The birds were booster vaccinated at 5 wk of age and were challenged with Texas GB strain of NDV at 6 wk of age. All birds vaccinated with LNDV or UVNDV had a specific CMI response to NDV, VN or HI NDV antibodies were detected in all CY-nontreated vaccinated birds and some of the CY-treated vaccinated birds that were found to have regenerated their B-cell function at 1 wk postbooster. The challenge results clearly revealed that CY-treated birds that had NDV-specific CMI and VN or HI antibody responses to LNDV or UVNDV were protected, as were the CY-nontreated vaccinated birds. However, birds that had NDV-specific CMI response but did not have VN or HI antibodies were not protected from challenge. The results from both strategies indicate that specific CMI to NDV by itself is not protective against virulent NDV challenge. The presence of VN or HI antibodies is necessary in providing protection from Newcastle disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10737655

Source DB:  PubMed          Journal:  Avian Dis        ISSN: 0005-2086            Impact factor:   1.577


  15 in total

1.  Oral treatment of chickens with lactobacilli influences elicitation of immune responses.

Authors:  Jennifer T Brisbin; Joshua Gong; Shahriar Orouji; Jessica Esufali; Amirul I Mallick; Payvand Parvizi; Patricia E Shewen; Shayan Sharif
Journal:  Clin Vaccine Immunol       Date:  2011-07-06

2.  Improved immunogenicity of Newcastle disease virus inactivated vaccine following DNA vaccination using Newcastle disease virus hemagglutinin-neuraminidase and fusion protein genes.

Authors:  Masoumeh Firouzamandi; Hassan Moeini; Davood Hosseini; Mohd Hair Bejo; Abdul Rahman Omar; Parvaneh Mehrbod; Aini Ideris
Journal:  J Vet Sci       Date:  2016-03-22       Impact factor: 1.672

3.  Molecular and biological characterization of the immunological potency of Newcastle disease virus oil emulsion-inactivated vaccines prepared from field isolate obtained from vaccinated chickens outbreak.

Authors:  Mohammed Ismail Hassan; Mohamed Wael Abd El-Azeem; Abdullah Selim; Serageldeen Sultan
Journal:  Braz J Microbiol       Date:  2019-12-16       Impact factor: 2.476

4.  Evaluating the efficacy of LaSota vaccination induced protection in chickens upon challenge with a genotype IV strain of Newcastle disease virus.

Authors:  S Bhuvaneswari; K G Tirumurugaan; P Venkatesan; P Manesh Kumar; K Kumanan
Journal:  Virusdisease       Date:  2017-09-26

5.  Assessment of cellular and mucosal immune responses in chicks to Newcastle disease oral pellet vaccine (D58 strain) using qPCR.

Authors:  P Shilpa; J John Kirubaharan; N Daniel Joy Chandran; N Gnanapriya
Journal:  Virusdisease       Date:  2014-10-24

6.  Newcastle disease virus (NDV) marker vaccine: an immunodominant epitope on the nucleoprotein gene of NDV can be deleted or replaced by a foreign epitope.

Authors:  Teshome Mebatsion; Marck J M Koolen; Leonie T C de Vaan; Niels de Haas; Marian Braber; Angela Römer-Oberdörfer; Paul van den Elzen; Pieter van der Marel
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

7.  Immunogenicity and protective efficacy of virosome based vaccines against Newcastle disease.

Authors:  Rajinder Singh; Prem C Verma; Satparkash Singh
Journal:  Trop Anim Health Prod       Date:  2009-09-02       Impact factor: 1.559

8.  Synthesis, characterization, and immune efficacy of layered double hydroxide@SiO2 nanoparticles with shell-core structure as a delivery carrier for Newcastle disease virus DNA vaccine.

Authors:  Kai Zhao; Guangyu Rong; Chen Guo; Xiaomei Luo; Hong Kang; Yanwei Sun; Chunxiao Dai; Xiaohua Wang; Xin Wang; Zheng Jin; Shangjin Cui; Qingshen Sun
Journal:  Int J Nanomedicine       Date:  2015-04-13

9.  The Effect of the Antimicrobial Peptide Plectasin on the Growth Performance, Intestinal Health, and Immune Function of Yellow-Feathered Chickens.

Authors:  Xinheng Zhang; Qiqi Zhao; Lijun Wen; Che Wu; Ziqi Yao; Zhuanqiang Yan; Ruoying Li; Liyi Chen; Feiyang Chen; Zi Xie; Feng Chen; Qingmei Xie
Journal:  Front Vet Sci       Date:  2021-06-23

10.  Preparation and efficacy of a live newcastle disease virus vaccine encapsulated in chitosan nanoparticles.

Authors:  Kai Zhao; Gang Chen; Xing-Ming Shi; Ting-Ting Gao; Wei Li; Yan Zhao; Feng-Qiang Zhang; Jin Wu; Xianlan Cui; Yun-Feng Wang
Journal:  PLoS One       Date:  2012-12-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.